| Serial Number | 98927796 |
| Word Mark | AMPA-NOVA |
| Filing Date | Monday, December 30, 2024 |
| Status | 661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED |
| Status Date | Monday, December 8, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
| Goods and Services | Pharmaceutical research and development services; scientific research in the nature of conducting clinical trials for others in the field of pharmaceutical preparations; pharmaceutical research services and pharmaceutical product evaluation, namely, conducting post-authorization research for the marketing of pharmaceutical preparations and evaluating epidemiological results; pharmaceutical research and development services in the field of anhedonia, major depressive disorder and mood disorders; scientific research in the nature of conducting clinical trials for others for pharmaceutical preparations for the treatment and prevention of anhedonia, major depressive disorder and mood disorders; pharmaceutical research services and pharmaceutical product evaluation, namely, conducting post-authorization research for the marketing of pharmaceutical preparations for the treatment and prevention of anhedonia, major depressive disorder and mood disorders, and evaluating epidemiological results for treatments for anhedonia, major depressive disorder and mood disorders; providing medical and scientific research information to patients and practitioners in the field of clinical trials, namely, as to the results of clinical trials; providing medical and scientific research information to patients and practitioners in the field of clinical trials, namely, as to the results of clinical trials pertaining to therapies and treatments for anhedonia, major depressive disorder and mood disorders |
| Goods and Services | Providing medical information; providing medical information relating to therapies and treatments for anhedonia, major depressive disorder and mood disorders |
| Pseudo Mark | AMPA NOVA |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, December 30, 2024 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, December 30, 2024 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Neurocrine Biosciences, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | San Diego, CA 92130 |
| Event Date | Event Description |
| Monday, December 30, 2024 | NEW APPLICATION ENTERED |
| Thursday, March 20, 2025 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Thursday, March 20, 2025 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Thursday, March 20, 2025 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Sunday, June 1, 2025 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Wednesday, June 4, 2025 | ASSIGNED TO EXAMINER |
| Sunday, June 8, 2025 | NON-FINAL ACTION WRITTEN |
| Sunday, June 8, 2025 | NON-FINAL ACTION E-MAILED |
| Sunday, June 8, 2025 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Friday, August 22, 2025 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Friday, August 22, 2025 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Monday, December 8, 2025 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Monday, December 8, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, December 8, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |